Recurrent Uterine Cervical Cancer: CT versus PET 5. Hricak H, Swift PS, Campos Z, Quivey JM, Gildengorin V, Goranson H. Irradiation of the cervix uteri: value of unen- hanced and contrast-enhanced MR imaging. Radiology 1993; 189:381-388 6. Williams MP, Husband JE, Heron CW, Cherryman GR, Koslin DB. Magnetic resonance imaging in recurrent carcinoma of the cervix. Br J Radiol 1989;62:544-550 7. Flueckiger F, Ebner F, Poschauko H, Tamussino K, Einspieler R, Ranner G. Cervical cancer: serial MR imaging before and after primary radiation therapy-a 2-year follow-up study. Radiology 1992;184:89-93 8. Di Chiro G. Positron emission tomography using [18F]fluo- rodeoxyglucose in brain tumors-a powerful diagnostic and prog- nostic tool. Invest Radiol 1988;22:360-371 9. Carlson V, Delclos L, Fletcher GH. Distant metastases in squa- mous-cell carcinoma of the uterine cervix. Radiology 1967; 88:961-966 10. Keettel WC, Van Voorhis LW, Latourette HB. Management of recurrent carcinoma of the cervix. Am J Obstet Gynecol 1968; 102:671-677 11. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106 12. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diag- noses. Radiology 1996;200:135-141 13. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluoro-de- oxyglucose positron emission tomography in the staging of re- current breast carcinoma. Anticancer Res 1997;17:1687-1692 14. Budinger TF, Brennan KM, Moses WW, Derenzo SE. Advances in positron tomography for oncology. Nucl Med Biol 1996;23: 659-667 15. Blahd WH, Brown CV, Khonsary SA, et al. PET scans of ab- dominal malignancy. World J Surg 1996;20:245-247 16. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic le- sions with positron emission tomography. Arch Surg 1998;133: 510-516 17. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:704-713 18. McGuirt WF, Greven KM, Keyes JW Jr, Williams DW 3rd, Watson N. Laryngeal radionecrosis versus recurrent cancer: a clinical approach. Ann Otol Rhinol Laryngol 1998;107:293-296 19. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998;23:3-7 20. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of re- current and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-620 21. Greven KM, Williams DW 3rd, Keyes JW Jr, McGuirt WF, Watson NE Jr, Case LD. Can positron emission tomography dis- tinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? Cancer J Sci Am 1997;3:353-357 22. Garner CM. Positron emission tomography: new hope for early detection of recurrent brain tumors. Cancer Nurs 1997; 20:277- 284 23. Schiepers C. Role of positron emission tomography in the stag- ing of lung cancer. Lung Cancer 1997;17(S)1:29-35 24. Simon GH, Nitzsche EU, Laubenberger JJ, Einert A, Moser E. PET imaging of recurrent medullary thyroid cancer. Nuk- learmedizin 1996;35:102-104 25. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997; 22:332-337 26. Hudgins PA, Burson JG, Gussack GS, Grist WJ. CT and MR ap- pearance of recurrent malignant head and neck neoplasms after resection and flap reconstruction. AJNR 1994;15: 1689-1694 27. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: nor- mal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. RadioGraphics 1998;18:805-823 Korean J Radiol 1(1), March 2000 55